Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.
BACKGROUND
Neuroblastoma has successfully served as a model system for the identification of neuroectoderm-derived oncogenes. However, in spite of various efforts, only a few clinically useful prognostic markers have been found. Here, we present a framework, which integrates DNA, RNA and tissue data to identify and prioritize genetic events that represent clinically relevant new therapeutic targets and prognostic biomarkers for neuroblastoma.


METHODS
A single-gene resolution aCGH profiling was integrated with microarray-based gene expression profiling data to distinguish genetic copy number alterations that were strongly associated with transcriptional changes in two neuroblastoma cell lines. FISH analysis using a hotspot tumor tissue microarray of 37 paraffin-embedded neuroblastoma samples and in silico data mining for gene expression information obtained from previously published studies including up to 445 healthy nervous system samples and 123 neuroblastoma samples were used to evaluate the clinical significance and transcriptional consequences of the detected alterations and to identify subsequently activated gene(s).


RESULTS
In addition to the anticipated high-level amplification and subsequent overexpression of MYCN, MEIS1, CDK4 and MDM2 oncogenes, the aCGH analysis revealed numerous other genetic alterations, including microamplifications at 2p and 12q24.11. Most interestingly, we identified and investigated the clinical relevance of a previously poorly characterized amplicon at 12q24.31. FISH analysis showed low-level gain of 12q24.31 in 14 of 33 (42%) neuroblastomas. Patients with the low-level gain had an intermediate prognosis in comparison to patients with MYCN amplification (poor prognosis) and to those with no MYCN amplification or 12q24.31 gain (good prognosis) (P = 0.001). Using the in silico data mining approach, we identified elevated expression of five genes located at the 12q24.31 amplicon in neuroblastoma (DIABLO, ZCCHC8, RSRC2, KNTC1 and MPHOSPH9). Among these, DIABLO showed the strongest activation suggesting a putative role in neuroblastoma progression.


CONCLUSIONS
The presented systematic and rapid framework, which integrates aCGH, gene expression and tissue data to obtain novel targets and biomarkers for cancer, identified a low-level gain of the 12q24.31 as a potential new biomarker for neuroblastoma progression. Furthermore, results of in silico data mining suggest a new neuroblastoma target gene, DIABLO, within this region, whose functional and therapeutic role remains to be elucidated in follow-up studies.
Wolf
Maija
M
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. maija.wolf@helsinki.fi
Korja
Miikka
M
Karhu
Ritva
R
Edgren
Henrik
H
Kilpinen
Sami
S
Ojala
Kalle
K
Mousses
Spyro
S
Kallioniemi
Anne
A
Haapasalo
Hannu
H
D014408:Biomarkers, Tumor / Q000235:genetics; D045744:Cell Line, Tumor; D002869:Chromosome Aberrations; D002881:Chromosomes, Human, Pair 12; D055028:Comparative Genomic Hybridization; D004273:DNA, Neoplasm / Q000235:genetics; D057225:Data Mining; D005784:Gene Amplification; D018628:Gene Dosage; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D009447:Neuroblastoma / Q000235:genetics* / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D011379:Prognosis; D012334:RNA, Neoplasm / Q000235:genetics; D014158:Transcription, Genetic
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm
Hum Mol Genet. 2007 Mar 15;16(6):640-50
17309881
BMC Bioinformatics. 2009 Jan 30;10 Suppl 1:S24
19208124
Med Pediatr Oncol. 2001 Jan;36(1):1-4
11464855
J Exp Med. 2003 Jul 21;198(2):341-7
12874265
Nature. 2009 Jun 18;459(7249):987-91
19536264
Cancer Res. 2006 Sep 1;66(17):8331-6
16951138
Am J Pathol. 1997 Jan;150(1):81-9
9006325
Genome Biol. 2004;5(10):R80
15461798
J Clin Oncol. 1997 Mar;15(3):1171-82
9060561
Cancer Genet Cytogenet. 2007 Aug;177(1):20-9
17693187
Cancer Res. 2006 Jun 15;66(12):6050-62
16778177
Neoplasia. 2003 Jan-Feb;5(1):53-62
12659670
N Engl J Med. 1999 Jun 24;340(25):1954-61
10379019
J Pathol. 1997 Apr;181(4):394-400
9196436
Cancer Genet Cytogenet. 2004 Oct 15;154(2):131-7
15474148
Genes Chromosomes Cancer. 2007 Oct;46(10):936-49
17647283
BMC Genomics. 2008 Jul 29;9:353
18664255
J Clin Oncol. 2009 Jan 10;27(2):289-97
19047291
BMC Genomics. 2004 Feb 03;5(1):11
15018647
Neuropsychopharmacology. 2004 Feb;29(2):373-84
14583743
Mol Psychiatry. 2006 Oct;11(10):965-78
16894394
Mod Pathol. 2005 Dec;18(12):1599-605
16258518
Cancer Res. 2002 Mar 15;62(6):1761-7
11912152
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7
15075390
Lancet Oncol. 2003 Aug;4(8):472-80
12901961
Genome Res. 2004 Aug;14(8):1462-73
15289471
BMC Genomics. 2004 Sep 20;5:70
15380028
Oncol Rep. 2004 Apr;11(4):797-802
15010875
N Engl J Med. 1985 Oct 31;313(18):1111-6
4047115
Genes Chromosomes Cancer. 2001 Oct;32(2):126-35
11550280
Genomics. 2005 Aug;86(2):127-41
15950434
BMC Cancer. 2004 Nov 23;4:84
15560849
Proc Natl Acad Sci U S A. 1984 Aug;81(15):4940-4
6589638
J Clin Oncol. 2005 Jan 20;23(3):448-54
15572731
Blood. 2006 Nov 15;108(10):3434-40
16868249
Hepatobiliary Pancreat Dis Int. 2006 Nov;5(4):580-3
17085346
Genes Chromosomes Cancer. 2005 Aug;43(4):390-403
15892104
Diagn Mol Pathol. 2007 Mar;16(1):1-8
17471152
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2173-8
14769913
Genome Biol. 2005;6(13):R112
16420671
Cancer. 1999 Jul 15;86(2):364-72
10421273
Nature. 1983 Sep 15-21;305(5931):245-8
6888561
BMC Cancer. 2006 Oct 26;6:256
17067390
Cytometry. 2001 Oct 1;45(2):83-6
11590619
Genome Biol. 2008;9(9):R139
18803840
N Engl J Med. 1996 Jan 25;334(4):225-30
8531999
J Clin Oncol. 1993 Aug;11(8):1466-77
8336186
Genomics. 2001 Jan 15;71(2):214-21
11161815
Cancer Genet Cytogenet. 1995 Jul 15;82(2):151-4
7664245
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70
11904358
Genes Chromosomes Cancer. 2008 Oct;47(10):819-34
18553563